Here are Top Health stories of the day
Supreme Court defers NEET PG Counselling 2021 hearing, Doctors launch Twitter storm demanding expedition
The painful wait of NEET PG aspirants has strung out once again as the Supreme Court deferred the hearing of a plea challenging the Centre and Medical Counselling Committee's (MCC) direction to provide 27 per cent reservation for OBC and 10 per cent for EWS category for PG Medical admissions via NEET PG Counselling 2021.
For more details, check out the full story on the link below:
Supreme court empowers Admission Supervisory Committee to initiate suo motu proceedings Against Private Medical Colleges
Upholding the Kerala High Court order, the Supreme Court has recently opined that the Admission Supervisory Committee and Fee Regulatory Committee for Professional Colleges of Kerala can initiate suo motu proceedings in respect of medical admissions made by the self-financing colleges.
Such an observation came from the Supreme Court as it was considering a plea challenging the scope and ambit of the powers of the Committee under Sections 4(6) and 4(7) of the Kerala Professional Colleges or Institutions (Prohibition Of Capitation Fee, Regulation Of Admission, Fixation Of NonExploitative Fee And Other Measures To Ensure Equity And Excellence in Professional Education) Act.
For more details, check out the full story on the link below:
MoS Dr Bhagwat Karad attends to medical emergency mid-air, PM Modi lauds gesture
Union Minister Dr Bhagwat Karad, who is a pediatrician by qualification, recently made headlines after he helped a co-passenger who was feeling uneasy on board a Delhi-Mumbai IndiGo flight on Tuesday.
Dr Karad's gesture of providing first aid to a co-passenger on an Indigo flight after the passenger complained of a giddiness mid air was appreciated by netizens and even Prime Minister Narendra Modi lauded him.
For more details, check out the full story on the link below:
MoS Dr Bhagwat Karad Attends To Medical Emergency Mid-Air, PM Modi Lauds Gesture
Glenmark gets CDSCO panel nod to market Remogliflozin, Teneligliptin, Metformin FDC drug
Granting permission for a local Phase III clinical trial and bioequivalence study waver, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has given its nod to pharma major Glenmark Pharma for manufacturing and marketing of an anti-diabetic Fixed Dose Combination (FDC) drug comprising of Remogliflozin etabonate 100mg, Teneligliptin 10mg and Metformin hydrochloride IP 500mg/1000mg.
However, the approval comes with a condition that the company should conduct a Phase IV Clinical Trial (CT) study in a significant number of patients. The committee also instructed the company to submit a Phase IV CT protocol within three months after receiving approval.
For more details, check out the full story on the link below:
Glenmark Gets CDSCO Panel Nod To Market Remogliflozin, Teneligliptin, Metformin FDC Drug
NMC Denies Approval to Four New Medical Colleges in Karnataka
In a major setback, the National Medical Commission (NMC) has denied approval for MBBS seats in four new medical colleges in Karnataka.
With NMC turning down the approval, it seems that the new medical colleges in Chikkamagaluru, Haveri, Yadgir and Chikkaballapur wouldn't be able to start functioning from 2021-2022.
For more details, check out the full story on the link below:
NMC Denies Approval To Four New Medical Colleges In Karnataka
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.